Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 513

1.

Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.

Duong VH, Baer MR, Hendrick F, Weiss SR, Sato M, Zeidan AM, Gore SD, Davidoff AJ.

Leuk Res. 2015 Mar 28. pii: S0145-2126(15)00083-1. doi: 10.1016/j.leukres.2015.03.013. [Epub ahead of print]

PMID:
25869077
2.

Feasibility randomized controlled trial of cognitive and behavioral interventions for depression symptoms in patients accessing drug and alcohol treatment.

Delgadillo J, Gore S, Ali S, Ekers D, Gilbody S, Gilchrist G, McMillan D, Hughes E.

J Subst Abuse Treat. 2015 Mar 12. pii: S0740-5472(15)00061-6. doi: 10.1016/j.jsat.2015.02.008. [Epub ahead of print]

PMID:
25819701
3.

Influence of Bi(3+)-doping on the magnetic and Mössbauer properties of spinel cobalt ferrite.

Gore SK, Mane RS, Naushad M, Jadhav SS, Zate MK, Alothman ZA, Hui BK.

Dalton Trans. 2015 Mar 24;44(14):6384-90. doi: 10.1039/c5dt00156k.

PMID:
25742879
5.

Endoscopic foraminal decompression for failed back surgery syndrome under local anesthesia.

Yeung A, Gore S.

Int J Spine Surg. 2014 Dec 1;8. doi: 10.14444/1022. eCollection 2014.

6.
7.

Sciatica: detection and confirmation by new method.

Gore S, Nadkarni S.

Int J Spine Surg. 2014 Dec 1;8. doi: 10.14444/1015. eCollection 2014.

8.

Cadmium toxicity in silversmith: Safety is never too much!

Senthilkumaran S, Ananth C, Gore SB, Thirumalaikolundusubramanian P.

Indian J Occup Environ Med. 2014 Sep-Dec;18(3):163. doi: 10.4103/0019-5278.146919. No abstract available.

9.

Current state of prognostication and risk stratification in myelodysplastic syndromes.

Zeidan AM, Gore SD, Padron E, Komrokji RS.

Curr Opin Hematol. 2015 Mar;22(2):146-54. doi: 10.1097/MOH.0000000000000110.

PMID:
25575032
10.

Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part d.

Davidoff AJ, Hendrick FB, Zeidan AM, Baer MR, Stuart BC, Shenolikar RA, Gore SD.

J Oncol Pract. 2015 Mar;11(2):e190-8. doi: 10.1200/JOP.2014.001527. Epub 2015 Jan 6.

PMID:
25563701
11.

Real-Life Experience of a Brief Arsenic Trioxide-Based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy.

Leech M, Morris L, Stewart M, Smith BD, Bashey A, Holland K, Solomon S, Zhang X, Carraway HE, Pratz K, Gore SD, Zeidan AM.

Clin Lymphoma Myeloma Leuk. 2014 Nov 15. pii: S2152-2650(14)00495-9. doi: 10.1016/j.clml.2014.11.001. [Epub ahead of print]

PMID:
25499624
12.

Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.

Hendrick F, Davidoff AJ, Zeidan AM, Gore SD, Baer MR.

Medicare Medicaid Res Rev. 2014 Nov 26;4(4). pii: mmrr2014-004-04-a02. doi: 10.5600/mmrr.004.04.a02. eCollection 2014. Erratum in: Medicare Medicaid Res Rev. 2014;4(4). pii: mmrr2014-004-04-a02_corrigendum.

13.

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, Karp JE, Gore SD, Kay NE, Jelinek DF, Witzig TE, Nowakowski GS, Kaufmann SH.

Blood. 2015 Jan 22;125(4):658-67. doi: 10.1182/blood-2014-04-571786. Epub 2014 Dec 1.

PMID:
25452615
14.

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.

Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS.

Cancer. 2015 Mar 15;121(6):876-82. doi: 10.1002/cncr.29145. Epub 2014 Nov 19.

PMID:
25410759
15.

Controlled Porosity Solubility Modulated Osmotic Pump Tablets of Gliclazide.

Banerjee A, Verma PR, Gore S.

AAPS PharmSciTech. 2014 Nov 7. [Epub ahead of print]

PMID:
25378281
16.

Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice.

Henry BD, Neill DR, Becker KA, Gore S, Bricio-Moreno L, Ziobro R, Edwards MJ, Mühlemann K, Steinmann J, Kleuser B, Japtok L, Luginbühl M, Wolfmeier H, Scherag A, Gulbins E, Kadioglu A, Draeger A, Babiychuk EB.

Nat Biotechnol. 2015 Jan;33(1):81-8. doi: 10.1038/nbt.3037. Epub 2014 Nov 2.

PMID:
25362245
17.

New strategies in acute promyelocytic leukemia: moving to an entirely oral, chemotherapy-free upfront management approach.

Zeidan AM, Gore SD.

Clin Cancer Res. 2014 Oct 1;20(19):4985-93. doi: 10.1158/1078-0432.CCR-13-2725.

PMID:
25274377
18.

Subdural hematoma in Plasmodium vivax malaria: Another Nail hammered on the coffin.

Senthilkumaran S, Ananth C, Gore SB, Thirumalaikolundusubramanian P.

Indian J Crit Care Med. 2014 Sep;18(9):636-7. doi: 10.4103/0972-5229.140157. No abstract available.

19.

Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients.

Neogi U, Rao SD, Bontell I, Verheyen J, Rao VR, Gore SC, Soni N, Shet A, Schülter E, Ekstrand ML, Wondwossen A, Kaiser R, Madhusudhan MS, Prasad VR, Sonnerborg A.

AIDS. 2014 Sep 24;28(15):2319-22. doi: 10.1097/QAD.0000000000000419.

PMID:
25102091
20.

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Katterling RP, Tallman MS, Gore SD.

Br J Haematol. 2014 Oct;167(1):62-8. doi: 10.1111/bjh.13008. Epub 2014 Jul 4.

PMID:
24995683
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk